Abigail Johnson — all tracked 13F funds
Holdings and reported values are aggregated from the latest 13F filings of every fund entity managed under this manager.
Embed this top-holdings widget →
| Fund | Holdings (Q3 2026) | Reported value |
|---|---|---|
| Fidelity Management & Research (FMR) | 5518 | $2,182.74B |
🚩 Holdings Prediction Model (2026-Q3)
Next-quarter Top-10 holdings and weights predicted from historical holdings plus per-stock price/volume (no look-ahead). Shows the prediction and backtest accuracy for the manager's core fund .
Predicted Top 10 — Next Quarter (2026-Q4)
Loading forecast…
Historical backtest (19 quarters): avg precision 92% · recall 92% · F1 92%
Form 4 Insider Transactions
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-10 | Sell | Avalyn Pharma Inc. | 47,889 | $30.28 | SEC filing |
| 2026-11-10 | Sell | Avalyn Pharma Inc. | 5,565 | $29.56 | SEC filing |
| 2026-11-09 | Sell | Avalyn Pharma Inc. | 1,339 | $29.75 | SEC filing |
| 2026-11-09 | Sell | Avalyn Pharma Inc. | 173,661 | $29.06 | SEC filing |
| 2026-06-26 | Sell | Beam Therapeutics Inc. | 251,488 | $35.26 | SEC filing |
| 2026-06-25 | Sell | Beam Therapeutics Inc. | 33,372 | $35.12 | SEC filing |
| 2026-05-01 | Conversion | Avalyn Pharma Inc. | 377,948 | — | SEC filing |
| 2026-05-01 | Conversion | Avalyn Pharma Inc. | 225,843 | — | SEC filing |
| 2026-05-01 | Conversion | Avalyn Pharma Inc. | 872,868 | — | SEC filing |
| 2026-05-01 | Conversion | Avalyn Pharma Inc. | 80,291 | — | SEC filing |
Why several funds per manager?
The SEC attributes a 13F filing to the management company with investment discretion. Big managers run multiple entities — hedge fund, advisers arm, private-investments vehicle — each filing separately. This page groups them so the manager-level picture is not split across filings. Who must file a 13F →
Where to go next
All fund managers → · Insider Transactions · Star manager new positions → · Browse all tracked funds →